Brief: Ocumension Therapeutics Says Approval Received For A Phase III Clinical Trial Of Ot-703 In China
09/06/2022 11:34
June 9 (Reuters) - Ocumension Therapeutics 1477.HK :
* APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-703
IN
CHINA FROM CDE OF NMPA
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application